IL161584A0 - Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use - Google Patents

Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use

Info

Publication number
IL161584A0
IL161584A0 IL16158402A IL16158402A IL161584A0 IL 161584 A0 IL161584 A0 IL 161584A0 IL 16158402 A IL16158402 A IL 16158402A IL 16158402 A IL16158402 A IL 16158402A IL 161584 A0 IL161584 A0 IL 161584A0
Authority
IL
Israel
Prior art keywords
methods
vectors containing
amino acid
nucleic acid
containing same
Prior art date
Application number
IL16158402A
Other languages
English (en)
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of IL161584A0 publication Critical patent/IL161584A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/235—Adenoviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10361—Methods of inactivation or attenuation
    • C12N2710/10362—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/17011—Spumavirus, e.g. chimpanzee foamy virus
    • C12N2740/17022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
    • C12N2760/14134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/55—Vector systems having a special element relevant for transcription from bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL16158402A 2001-11-21 2002-11-20 Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use IL161584A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33195101P 2001-11-21 2001-11-21
US36679802P 2002-03-22 2002-03-22
PCT/US2002/033645 WO2003046124A2 (en) 2001-11-21 2002-11-20 Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use

Publications (1)

Publication Number Publication Date
IL161584A0 true IL161584A0 (en) 2004-09-27

Family

ID=26987985

Family Applications (5)

Application Number Title Priority Date Filing Date
IL16158402A IL161584A0 (en) 2001-11-21 2002-11-20 Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
IL161584A IL161584A (en) 2001-11-21 2004-04-22 Recombinant adenoid viruses host cells and compounds containing them and their uses
IL223344A IL223344A (en) 2001-11-21 2012-11-29 Adno recombinant virus with a shell containing the hexane protein adpan6 and its uses
IL230292A IL230292A (en) 2001-11-21 2014-01-02 Recombinant adenoviral envelope containing hexon protein adsv25
IL231502A IL231502A (en) 2001-11-21 2014-03-13 Add a capsid-containing recombinant virus containing the hexon-adpan5 protein and their uses

Family Applications After (4)

Application Number Title Priority Date Filing Date
IL161584A IL161584A (en) 2001-11-21 2004-04-22 Recombinant adenoid viruses host cells and compounds containing them and their uses
IL223344A IL223344A (en) 2001-11-21 2012-11-29 Adno recombinant virus with a shell containing the hexane protein adpan6 and its uses
IL230292A IL230292A (en) 2001-11-21 2014-01-02 Recombinant adenoviral envelope containing hexon protein adsv25
IL231502A IL231502A (en) 2001-11-21 2014-03-13 Add a capsid-containing recombinant virus containing the hexon-adpan5 protein and their uses

Country Status (19)

Country Link
US (5) US7247472B2 (de)
EP (4) EP2301582B1 (de)
JP (9) JP2005511035A (de)
KR (1) KR100987360B1 (de)
CN (1) CN1578678B (de)
AU (1) AU2002365366B2 (de)
BR (1) BR0214350A (de)
CA (3) CA2990322A1 (de)
CO (1) CO5590973A2 (de)
HU (3) HU230364B1 (de)
IL (5) IL161584A0 (de)
MX (2) MX351516B (de)
NO (3) NO332692B1 (de)
NZ (3) NZ564586A (de)
PH (1) PH12016500338A1 (de)
PL (1) PL209133B1 (de)
SG (2) SG2013034475A (de)
WO (1) WO2003046124A2 (de)
ZA (1) ZA200403117B (de)

Families Citing this family (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040136963A1 (en) * 2001-06-22 2004-07-15 The Trustees Of The University Of Pennsylvania Simian adenovirus vectors and methods of use
AU2002322285A1 (en) 2001-06-22 2003-01-08 The Trustees Of The University Of Pennsylvania Method for rapid screening of bacterial transformants and novel simian adenovirus proteins
HU230364B1 (hu) 2001-11-21 2016-03-29 The Trustees Of The University Of Pennsylvania Simian adenovírus nukleinsav és aminosav-szekvencia, azt tartalmazó vektorok, és eljárások annak alkalmazására
EP2277533B1 (de) 2002-10-23 2016-07-20 GlaxoSmithKline Biologicals S.A. Malaria-Impfverfahren
US7291498B2 (en) 2003-06-20 2007-11-06 The Trustees Of The University Of Pennsylvania Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses
US7491508B2 (en) * 2003-06-20 2009-02-17 The Trustees Of The University Of Pennsylvania Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses
SI2163260T1 (sl) 2004-01-23 2017-07-31 Msd Italia S.R.L. Nosilci šimpanzjih adenovirusnih cepiv
EP1742657B1 (de) 2004-04-28 2013-11-06 The Trustees of The University of Pennsylvania Immunisierungstherapie mit e4-deletiertem adenovirus-prime und e1-deletiertem adenovirus-boost
CA2563538C (en) 2004-04-28 2013-12-17 The Trustees Of The University Of Pennsylvania Sequential delivery of immunogenic molecules via adenovirus and adeno-associated virus-mediated administrations
EP1773303A2 (de) * 2004-05-25 2007-04-18 Chimeracore, Inc. Selbstmontierendes nanopartikel-wirkstofffreisetzungssystem
GB0417494D0 (en) 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
NZ581306A (en) 2004-11-16 2011-03-31 Crucell Holland Bv Multivalent vaccines comprising recombinant viral vectors
WO2006094384A1 (en) * 2005-03-08 2006-09-14 Genesense Technologies Inc. Use of interleukin 17e for the treatment of cancer
GB0513421D0 (en) 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
ATE460922T1 (de) * 2006-04-07 2010-04-15 Chimeros Inc Zusammensetzungen und verfahren zur behandlung von b-zellen-malignomen
EP2012822B1 (de) * 2006-04-28 2010-01-20 The Trustees of the University of Pennsylvania Modifiziertes adenovirus-hexon-protein und anwendungen davon
US20090246220A1 (en) 2006-08-28 2009-10-01 Ertl Hildegund C J Constructs for enhancing immune responses
CA2679410C (en) 2007-03-02 2017-01-17 Glaxosmithkline Biologicals S.A. Novel method and compositions
CA2683063A1 (en) * 2007-04-09 2008-10-16 Chimeros, Inc. Self-assembling nanoparticle drug delivery system
WO2009105084A2 (en) * 2007-11-28 2009-08-27 The Trustees Of The University Of Pennsylvania Simian subfamily c adenoviruses sadv-40, -31, and-34 and uses thereof
PT2220242T (pt) 2007-11-28 2017-04-03 Univ Pennsylvania Adenovírus símio da subfamília b sadv-28,27,-29,-32,-33 e -35 e suas utilizações
KR101761691B1 (ko) * 2007-11-28 2017-07-26 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 유인원 ｅ 아데노바이러스 ｓａｄｖ-39, -25.2, -26, -30, -37, 및 -38
AU2014203073B2 (en) * 2007-11-28 2016-07-07 The Trustees Of The University Of Pennsylvania Simian E adenovirus SAdV-30
EP2250255A2 (de) * 2008-03-04 2010-11-17 The Trustees of the University of Pennsylvania Simian-adenoviren sadv-36, -42.1, -42.2 und -44 sowie anwendungen davon
US9217155B2 (en) 2008-05-28 2015-12-22 University Of Massachusetts Isolation of novel AAV'S and uses thereof
US8940290B2 (en) * 2008-10-31 2015-01-27 The Trustees Of The University Of Pennsylvania Simian adenoviruses SAdV-43, -45, -46, -47, -48, -49, and -50 and uses thereof
WO2010085984A1 (en) * 2009-02-02 2010-08-05 Okairos Ag Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
CA2749325C (en) * 2009-02-02 2021-03-30 Okairos Ag Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
EP2408933A2 (de) 2009-03-17 2012-01-25 MDxHealth SA Verbesserter genexpressionsnachweis
WO2010120874A2 (en) 2009-04-14 2010-10-21 Chimeros, Inc. Chimeric therapeutics, compositions, and methods for using same
WO2010138263A2 (en) 2009-05-28 2010-12-02 University Of Massachusetts Novel aav 's and uses thereof
WO2010138675A1 (en) 2009-05-29 2010-12-02 The Trustees Of The University Of Pennsylvania Simian adenovirus 41 and uses thereof
PH12012500908A1 (en) 2009-11-09 2017-08-23 Genvec Inc Methods of propagating monkey adenoviral vectors
WO2011057254A2 (en) * 2009-11-09 2011-05-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Simian adenoviral vector-based vaccines
WO2011129468A1 (en) 2010-04-14 2011-10-20 Mogam Biotechnology Research Institute Hexon isolated from simian adenovirus serotype 19, hypervariable region thereof and chimeric adenovirus using the same
US9272053B2 (en) 2010-04-23 2016-03-01 University Of Massachusetts AAV-based treatment of cholesterol-related disorders
EP3567106A1 (de) 2010-04-23 2019-11-13 University of Massachusetts Auf das zns abzielende aav-vektoren und verfahren zur verwendung davon
CA2833905C (en) 2010-04-23 2019-09-10 University Of Massachusetts Multicistronic expression constructs
EP3333265B1 (de) * 2010-05-14 2020-02-05 Oregon Health & Science University Rekombinante hcmv- und rhcmv-vektoren die ein heterologes antigen aus dem hepatitis b virus kodieren und deren verwendungen
WO2012021730A2 (en) 2010-08-11 2012-02-16 Genvec, Inc. Respiratory syncytial virus (rsv) vaccine
CN103118702A (zh) 2010-09-20 2013-05-22 克鲁塞尔荷兰公司 活动性结核病的治疗性接种
AU2011332025B2 (en) 2010-11-23 2015-06-25 The Trustees Of The University Of Pennsylvania Subfamily E simian adenoviruses A1321, A1325, A1295, A1309 and A1322 and uses thereof
EP2658979B1 (de) 2010-12-27 2018-02-14 Alexion Pharmaceuticals, Inc. Zusammensetzungen mit natriuretischen peptiden und verwendungsverfahren dafür
WO2012089231A1 (en) * 2010-12-30 2012-07-05 Okairòs Ag Paramyxovirus vaccines
US9267112B2 (en) 2011-05-10 2016-02-23 The Regents Of The University Of California Adenovirus isolated from Titi Monkeys
US10221218B2 (en) 2011-05-10 2019-03-05 The Regents Of The University Of California Adenovirus isolated from titi monkeys
GB201108879D0 (en) * 2011-05-25 2011-07-06 Isis Innovation Vector
TWI623618B (zh) 2011-07-12 2018-05-11 傳斯堅公司 Ｈｂｖ聚合酶突變體
JP2014527072A (ja) 2011-09-09 2014-10-09 バイオメド リアルティー， エル．ピー． ウイルスタンパク質の集合を制御するための方法および組成物
US20140348791A1 (en) * 2011-09-09 2014-11-27 Beth Israel Deaconess Medical Center, Inc. Modified adenoviral vectors and methods of treatment using same
WO2013045658A1 (en) 2011-09-29 2013-04-04 Transgene Sa Immunotherapy composition and regimen for treating hepatitis c virus infection
WO2013045668A2 (en) 2011-09-29 2013-04-04 Transgene Sa Immunotherapy composition and regimen for treating hepatitis c virus infection
CN107937440A (zh) * 2011-10-05 2018-04-20 金维克有限公司 猴腺病毒(大猩猩)或腺病毒载体及其使用方法
SG11201401605QA (en) 2011-10-19 2014-09-26 Alexion Pharma Holding Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
WO2013063019A1 (en) 2011-10-28 2013-05-02 The Wistar Institute Of Anatomy And Biology Methods and compositions for enhancing the therapeutic effect of anti-tumor t cells
US10238755B2 (en) 2011-11-30 2019-03-26 The Wistar Institute Of Anatomy And Biology Methods and compositions for regulation of cell aging, carcinogenesis and reprogramming
SG10201609511XA (en) 2012-05-18 2016-12-29 Univ Pennsylvania Subfamily e simian adenoviruses a1302, a1320, a1331 and a1337 and uses thereof
US9861693B2 (en) 2012-09-07 2018-01-09 Emory University HIV immune stimulating compositions comprising recombinantly expressed pili on bacteria and methods related thereto
WO2014047261A1 (en) * 2012-09-19 2014-03-27 Beth Israel Deaconess Medical Center, Inc. Viruses associated with immunodeficiency and enteropathy and methods using same
ES3040856T3 (en) 2012-11-16 2025-11-05 Beth Israel Deaconess Medical Ct Inc Recombinant adenoviruses and use thereof
EP2946016A4 (de) * 2013-01-15 2016-11-23 Univ California Adenoviren und deren verwendung
US9624510B2 (en) 2013-03-01 2017-04-18 The Wistar Institute Adenoviral vectors comprising partial deletions of E3
SG11201507393TA (en) 2013-03-14 2015-10-29 Salk Inst For Biological Studi Oncolytic adenovirus compositions
US9402888B2 (en) 2013-03-14 2016-08-02 The Wistar Institute Of Anatomy And Biology Methods and compositions for treating cancer
HUE043042T2 (hu) * 2013-11-01 2019-07-29 Pfizer Vektorok prosztatához kapcsolódó antigének expressziójára
US10577627B2 (en) 2014-06-09 2020-03-03 Voyager Therapeutics, Inc. Chimeric capsids
PL3198009T3 (pl) 2014-09-24 2022-01-24 Salk Institute For Biological Studies Onkolityczne wirusy nowotworowe i sposoby zastosowania
DK3200815T3 (da) 2014-10-02 2021-05-10 Wistar Inst Fremgangsmåder og sammensætninger til behandling af cancer
US10941452B2 (en) 2014-10-06 2021-03-09 The Trustees Of The University Of Pennsylvania Compositions and methods for isolation of circulating tumor cells (CTC)
RU2020140209A (ru) 2014-10-21 2021-01-25 Юниверсити Оф Массачусетс Варианты рекомбинантных aav и их применения
CN107106689A (zh) 2014-11-05 2017-08-29 沃雅戈治疗公司 用于治疗帕金森病的aadc多核苷酸
IL292999A (en) 2014-11-14 2022-07-01 Voyager Therapeutics Inc Compositions and methods of treating amyotrophic lateral sclerosis (als)
CN112410338A (zh) 2014-11-14 2021-02-26 沃雅戈治疗公司 调节性多核苷酸
WO2016094783A1 (en) 2014-12-12 2016-06-16 Voyager Therapeutics, Inc. Compositions and methods for the production of scaav
ES3011733T3 (en) 2015-02-13 2025-04-08 Transgene Immunotherapeutic vaccine and antibody combination therapy
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
KR102535670B1 (ko) * 2015-06-12 2023-05-22 글락소스미스클라인 바이오로지칼즈 에스.에이. 아데노바이러스 폴리뉴클레오티드 및 폴리펩티드
WO2017096162A1 (en) 2015-12-02 2017-06-08 Voyager Therapeutics, Inc. Assays for the detection of aav neutralizing antibodies
US11208468B2 (en) 2016-02-18 2021-12-28 The Wistar Institute Of Anatomy And Biology Methods and compositions for treating melanoma
JP7015551B2 (ja) 2016-02-23 2022-02-15 ソーク インスティテュート フォー バイオロジカル スタディーズ ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現
JP7054527B2 (ja) 2016-02-23 2022-04-14 ソーク インスティテュート フォー バイオロジカル スタディーズ アデノウイルスの複製動態を測定するための高スループットアッセイ
WO2017189964A2 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
US11326182B2 (en) 2016-04-29 2022-05-10 Voyager Therapeutics, Inc. Compositions for the treatment of disease
EP3452081A1 (de) 2016-05-04 2019-03-13 Transgene SA Kombinationstherapie mit cpg-tlr9-liganden
KR20220108216A (ko) 2016-05-18 2022-08-02 보이저 테라퓨틱스, 인크. 헌팅톤 질환을 치료하기 위한 조성물 및 방법
SG11201809699XA (en) 2016-05-18 2018-12-28 Voyager Therapeutics Inc Modulatory polynucleotides
US10953108B2 (en) * 2016-08-01 2021-03-23 The Wistar Institute Of Anatomy And Biology Compositions and methods of replication deficient adenoviral vectors for vaccine applications
IL315358A (en) 2016-08-18 2024-11-01 Univ California CRISPR-CAS genome engineering using a modular AAV delivery system
CN110650673B (zh) 2016-08-30 2024-04-09 加利福尼亚大学董事会 用于生物医学靶向和递送的方法以及用于实践该方法的装置和系统
EP3522920A2 (de) 2016-10-10 2019-08-14 Transgene SA Immuntherapeutisches produkt und mdsc-modulator-kombinationstherapie
CA3040483A1 (en) 2016-10-13 2018-04-19 University Of Massachusetts Aav capsid designs
WO2018111767A1 (en) 2016-12-12 2018-06-21 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
JP2020518259A (ja) 2017-05-05 2020-06-25 ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ハンチントン病治療組成物および方法
SG11201909870SA (en) 2017-05-05 2019-11-28 Voyager Therapeutics Inc Compositions and methods of treating amyotrophic lateral sclerosis (als)
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
JP7229989B2 (ja) 2017-07-17 2023-02-28 ボイジャー セラピューティクス インコーポレイテッド 軌道アレイガイドシステム
TWI832036B (zh) 2017-08-03 2024-02-11 美商航海家醫療公司 用於aav之遞送之組合物及方法
MX2020003042A (es) 2017-09-29 2020-11-18 Voyager Therapeutics Inc Rescate del fenotipo neurológico central y periférico de la ataxia de friedreich mediante administración intravenosa.
EP4454654A3 (de) 2017-10-16 2025-02-19 Voyager Therapeutics, Inc. Behandlung von amyotropher lateralsklerose (als)
US11434502B2 (en) 2017-10-16 2022-09-06 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (ALS)
EP3723771A4 (de) * 2017-12-11 2022-04-06 Beth Israel Deaconess Medical Center, Inc. Rekombinante adenoviren und verwendungen davon
JP7430395B2 (ja) 2018-04-09 2024-02-13 ソーク インスティテュート フォー バイオロジカル スタディーズ 複製特質が増強された腫瘍溶解性アデノウイルス組成物
EP3794126A1 (de) 2018-05-15 2021-03-24 Voyager Therapeutics, Inc. Zusammensetzungen und verfahren zur behandlung von morbus parkinson
WO2019241486A1 (en) 2018-06-13 2019-12-19 Voyager Therapeutics, Inc. Engineered 5' untranslated regions (5' utr) for aav production
US11510999B2 (en) 2018-07-17 2022-11-29 Helixmith Co., Ltd Treatment of neuropathy with DNA constructs expressing IGF-1 isoforms
JP2021530548A (ja) 2018-07-24 2021-11-11 ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics, Inc. 遺伝子治療製剤を生産するための系および方法
CN113383010B (zh) 2018-09-28 2025-09-09 沃雅戈治疗公司 具有经工程化改造的启动子的共济蛋白表达构建体及其使用方法
TW202035689A (zh) 2018-10-04 2020-10-01 美商航海家醫療公司 測量病毒載體粒子的效價及強度之方法
JP2022512621A (ja) 2018-10-05 2022-02-07 ボイジャー セラピューティクス インコーポレイテッド Ａａｖ産生タンパク質をコードする操作された核酸コンストラクト
EP3867389A1 (de) 2018-10-15 2021-08-25 Voyager Therapeutics, Inc. Expressionsvektoren zur massenproduktion von raav im baculovirus/sf9-system
CN113924115A (zh) 2019-01-31 2022-01-11 俄勒冈健康与科学大学 用于aav衣壳的使用转录依赖性定向进化的方法
CN114269363A (zh) * 2019-04-17 2022-04-01 威斯达研究所 用于hiv疫苗应用的复制缺陷型腺病毒载体
CN116322740A (zh) 2020-07-13 2023-06-23 特兰斯吉恩股份有限公司 免疫抑制的治疗
EP4284335A1 (de) 2021-02-01 2023-12-06 RegenxBio Inc. Gentherapie für neuronale ceroid-lipofuscinosen
CN112831524B (zh) * 2021-02-20 2023-06-13 苏州相奕生物技术有限公司 人工改造的重组腺病毒载体、由其包装的病毒及其应用
CA3213066A1 (en) * 2021-03-29 2022-10-06 Soo-Ok Kim Recombinant chimeric adenoviral vector substituted by knob gene of chimpanzee adenovirus serotype 6, and application thereof
WO2022218997A1 (en) 2021-04-12 2022-10-20 Centre National De La Recherche Scientifique (Cnrs) Novel universal vaccine presenting system
KR102874372B1 (ko) * 2022-03-03 2025-10-23 (주)진매트릭스 사스-코로나바이러스-2 감염증 예방용 재조합 발현 벡터 및 그 응용
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5240846A (en) 1989-08-22 1993-08-31 The Regents Of The University Of Michigan Gene therapy vector for cystic fibrosis
US6174666B1 (en) 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
JPH10507758A (ja) 1994-10-19 1998-07-28 ジェネティック セラピー，インコーポレイテッド アデノウイルスおよび免疫抑制剤同時反復投与を伴う遺伝子治療
US5856152A (en) 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
DK0787200T3 (da) 1994-10-28 2005-08-15 Univ Pennsylvania Forbedret adenovirus og fremgangsmåder til anvendelse heraf
US6127525A (en) * 1995-02-21 2000-10-03 Cornell Research Foundation, Inc. Chimeric adenoviral coat protein and methods of using same
US5770442A (en) * 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
US5698202A (en) 1995-06-05 1997-12-16 The Wistar Institute Of Anatomy & Biology Replication-defective adenovirus human type 5 recombinant as a rabies vaccine carrier
AU6261696A (en) 1995-06-05 1996-12-24 Trustees Of The University Of Pennsylvania, The A replication-defective adenovirus human type 5 recombinant as a vaccine carrier
WO1998010087A1 (en) 1996-09-06 1998-03-12 Trustees Of The University Of Pennsylvania Chimpanzee adenovirus vectors
JP2001500015A (ja) 1996-09-06 2001-01-09 トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Ｔ７ポリメラーゼを利用する組換えアデノ随伴ウイルスの誘導可能な製造方法
US5922315A (en) * 1997-01-24 1999-07-13 Genetic Therapy, Inc. Adenoviruses having altered hexon proteins
US5891994A (en) 1997-07-11 1999-04-06 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
JP2001517454A (ja) 1997-09-19 2001-10-09 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 組換えアデノ随伴ウイルスの産生に有用な方法および細胞株
CA2303768C (en) 1997-09-19 2009-11-24 The Trustees Of The University Of Pennsylvania Methods and vector constructs useful for production of recombinant aav
GB9720585D0 (en) 1997-09-26 1997-11-26 Smithkline Beecham Biolog Vaccine
CA2324225A1 (en) 1998-03-20 1999-09-23 The Trustees Of The University Of Pennsylvania Compositions and methods for helper-free production of recombinant adeno-associated viruses
US20030017138A1 (en) * 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
WO2000011140A1 (en) 1998-08-20 2000-03-02 The Wistar Institute Of Anatomy And Biology Methods of augmenting mucosal immunity through systemic priming and mucosal boosting
US6258595B1 (en) 1999-03-18 2001-07-10 The Trustees Of The University Of Pennsylvania Compositions and methods for helper-free production of recombinant adeno-associated viruses
WO2001002607A1 (en) 1999-07-06 2001-01-11 Merck & Co., Inc. Adenovirus carrying gag gene hiv vaccine
OA12168A (en) 2000-01-31 2006-05-08 Smithkline Beecham Biolog Vaccine for the prophylactic or therapeutic immunization against HIV.
US6740525B2 (en) 2000-02-09 2004-05-25 Genvec, Inc. Adenoviral capsid containing chimeric protein IX
CZ304169B6 (cs) 2001-06-22 2013-12-04 The Wistar Institute Of Anatomy And Biology Replikacne defektní opicí adenovirový vektor, zpusob jeho prípravy a lécivo, imunogenní kompozice a vakcína obsahující rekombinantní adenovirus
AU2002322285A1 (en) * 2001-06-22 2003-01-08 The Trustees Of The University Of Pennsylvania Method for rapid screening of bacterial transformants and novel simian adenovirus proteins
US20040136963A1 (en) 2001-06-22 2004-07-15 The Trustees Of The University Of Pennsylvania Simian adenovirus vectors and methods of use
HU230364B1 (hu) 2001-11-21 2016-03-29 The Trustees Of The University Of Pennsylvania Simian adenovírus nukleinsav és aminosav-szekvencia, azt tartalmazó vektorok, és eljárások annak alkalmazására
EP2277533B1 (de) 2002-10-23 2016-07-20 GlaxoSmithKline Biologicals S.A. Malaria-Impfverfahren
US7291498B2 (en) 2003-06-20 2007-11-06 The Trustees Of The University Of Pennsylvania Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses
US7491508B2 (en) 2003-06-20 2009-02-17 The Trustees Of The University Of Pennsylvania Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses
CA2563538C (en) 2004-04-28 2013-12-17 The Trustees Of The University Of Pennsylvania Sequential delivery of immunogenic molecules via adenovirus and adeno-associated virus-mediated administrations
EP1743028A2 (de) 2004-04-28 2007-01-17 The Trustees Of The University Of Pennsylvania Polyvalente virale vektoren, und system zur produktion derselben
EP1742657B1 (de) 2004-04-28 2013-11-06 The Trustees of The University of Pennsylvania Immunisierungstherapie mit e4-deletiertem adenovirus-prime und e1-deletiertem adenovirus-boost
EA200702190A1 (ru) 2005-05-12 2008-04-28 Глаксо Груп Лимитед Вакцинная композиция
EP2012822B1 (de) * 2006-04-28 2010-01-20 The Trustees of the University of Pennsylvania Modifiziertes adenovirus-hexon-protein und anwendungen davon
CA2657353A1 (en) 2006-07-18 2008-01-24 Glaxosmithkline Biologicals S.A. Vaccines for malaria
CA2679410C (en) 2007-03-02 2017-01-17 Glaxosmithkline Biologicals S.A. Novel method and compositions
EP2777185B1 (de) 2011-10-13 2016-08-24 Telefonaktiebolaget LM Ericsson (publ) Verfahren und knoten zur kanalschätzung

Also Published As

Publication number Publication date
CO5590973A2 (es) 2005-12-30
SG2013034475A (en) 2016-10-28
NO335438B1 (no) 2014-12-15
EP1453543A2 (de) 2004-09-08
IL231502A0 (en) 2014-04-30
CA2852277A1 (en) 2003-06-05
US20170119873A9 (en) 2017-05-04
NO20042191L (no) 2004-05-26
PL373602A1 (en) 2005-09-05
JP2011055835A (ja) 2011-03-24
EP2301582A1 (de) 2011-03-30
KR20040054796A (ko) 2004-06-25
HUP1400619A2 (en) 2006-01-30
JP5715749B2 (ja) 2015-05-13
US7247472B2 (en) 2007-07-24
SG165153A1 (en) 2010-10-28
BR0214350A (pt) 2005-05-10
JP2017035111A (ja) 2017-02-16
JP2009136296A (ja) 2009-06-25
EP2301582B1 (de) 2017-07-12
HUP0500987A3 (en) 2008-05-28
US8603459B2 (en) 2013-12-10
WO2003046124A3 (en) 2003-11-20
EP3108899A1 (de) 2016-12-28
CA2990322A1 (en) 2003-06-05
CA2852277C (en) 2018-02-20
JP2005511035A (ja) 2005-04-28
CN1578678B (zh) 2010-05-26
NZ550416A (en) 2008-06-30
US9133483B2 (en) 2015-09-15
KR100987360B1 (ko) 2010-10-12
NO20130590L (no) 2004-05-26
NO334512B1 (no) 2014-03-24
US20120093778A1 (en) 2012-04-19
NZ564586A (en) 2009-09-25
JP2015057052A (ja) 2015-03-26
JP2017035110A (ja) 2017-02-16
PL209133B1 (pl) 2011-07-29
JP2013252144A (ja) 2013-12-19
JP2017070292A (ja) 2017-04-13
AU2002365366B2 (en) 2007-05-10
ZA200403117B (en) 2005-03-30
JP2015057051A (ja) 2015-03-26
US8105574B2 (en) 2012-01-31
IL223344A (en) 2015-04-30
IL230292A (en) 2016-08-31
MX351516B (es) 2017-10-17
HU230488B1 (hu) 2016-08-29
MXPA04004876A (es) 2004-07-30
AU2002365366A1 (en) 2003-06-10
US20080090281A1 (en) 2008-04-17
IL231502A (en) 2017-04-30
NO20120337L (no) 2004-05-26
IL161584A (en) 2015-05-31
HU230365B1 (hu) 2016-03-29
CN1578678A (zh) 2005-02-09
EP2286841A1 (de) 2011-02-23
HU230364B1 (hu) 2016-03-29
PH12016500338A1 (en) 2018-03-26
US20050069866A1 (en) 2005-03-31
EP1453543B1 (de) 2017-08-30
CA2466431C (en) 2014-08-05
IL223344A0 (en) 2013-02-03
US20150352203A1 (en) 2015-12-10
CA2466431A1 (en) 2003-06-05
EP1453543A4 (de) 2006-12-06
HUP0500987A2 (en) 2006-01-30
NZ532383A (en) 2007-03-30
US20140065105A1 (en) 2014-03-06
NO332692B1 (no) 2012-12-10
WO2003046124A2 (en) 2003-06-05

Similar Documents

Publication Publication Date Title
IL231502A0 (en) Simian adenoid virus nucleic acid and amino acid sequences, vectors containing the same and methods of use
AU2002324700A1 (en) Nucleic acid and amino acid sequences involved in pain
AU2002323249A1 (en) Novel salicylic acid-binding protein encoding nucleic acid, sabp2, and methods of use thereof
AU4390099A (en) Nucleotide sequences of the apple lrpkm1 gene, encoded amino acid sequence and uses thereof
AU2001278655A1 (en) Novel nucleic acid and amino acid sequences
PL373834A1 (en) Insulin mimetic amino acid sequences
AU2002226307A1 (en) Artificial chromosomes comprising concatemers of expressible nucleotide sequences
HK1069313A (en) Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
AU2640002A (en) Sequences upstream of the carp gene, vectors containing them and uses thereof
AU2001264845A1 (en) Nucleotide sequences encoding ramosa 1 gene and methods of use for same
IL129734A0 (en) Novel nucleic acid and amino acid sequences
AU2002368251A1 (en) Characterizing nucleic acid and amino acid sequences in silico
IL128852A0 (en) Novel nucleic acid and amino acid sequences
EP1390486A4 (de) Isolierte menschliche aminoacylase, menschliche aminoacylase codierende nukleinsäuremoleküle sowie verwendungen davon
IL128252A0 (en) Novel nucleic acid and amino acid sequences
NZ513990A (en) Novel nucleotide and amino acid sequences
IL128131A0 (en) Novel nucleic acid and amino acid sequences
WO2001072842A3 (en) Human 7-transmembrane proteins and polynucleotides encoding the same
AU2002322404A8 (en) Novel human proteins, polynucleotides encoding them and methods of using the same
IL135341A0 (en) Novel nucleic acid and amino acid sequences
IL134932A0 (en) Novel nucleic acid and amino acid sequences
IL135310A0 (en) Novel nucleic acid and amino acid sequences
IL137345A0 (en) Novel nucleic acid and amino acid sequences
IL133173A0 (en) Novel nucleic acid and amino acid sequences
IL133767A0 (en) Novel nucleic acid and amino acid sequences